financetom
Business
financetom
/
Business
/
Texas sues Tylenol makers J&J and Kenvue, claiming they hid drug's autism risks
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Texas sues Tylenol makers J&J and Kenvue, claiming they hid drug's autism risks
Oct 28, 2025 7:09 AM

Oct 28 (Reuters) - The makers of Tylenol, Johnson &

Johnson ( JNJ ) and Kenvue, were sued on Tuesday by

Texas Attorney General Ken Paxton, who accused them of knowingly

hiding the drug's links to autism and attention deficit

hyperactivity disorder.

Paxton, a Republican, sued five weeks after Republican

President Donald Trump said

using Tylenol during pregnancy can cause autism in

children. Trump is not a doctor, and his claim is unproven and

not backed by scientific evidence.

Johnson & Johnson ( JNJ ) sold Tylenol for more than six decades,

and its former Kenvue unit has sold it since 2023 after being

spun off. The pain reliever is known generically as

acetaminophen.

Kenvue has repeatedly defended Tylenol's safety, and in a

statement said it would defend against Paxton's lawsuit.

"Acetaminophen is the safest pain reliever option for

pregnant women as needed throughout their entire pregnancy,"

Kenvue said. "We are deeply concerned by the perpetuation of

misinformation on the safety of acetaminophen."

In a separate statement, Johnson & Johnson ( JNJ ) did not comment

on Paxton's lawsuit, and said Kenvue is responsible for "all

rights and liabilities associated with the sale of its

over-the-counter products, including Tylenol."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Viking Therapeutics misses Q3 profit estimates
Viking Therapeutics misses Q3 profit estimates
Oct 22, 2025
Overview * Viking Therapeutics ( VKTX ) reports Q3 net loss of $90.8 mln, missing analyst expectations * Company maintains strong cash position of $715 mln to support ongoing clinical trials * VK2735 Phase 2 VENTURE study shows up to 12.2% weight loss, meeting primary endpoints Outlook * Company expects to complete VANQUISH-1 enrollment by end of 2025 * Viking...
Eagle Bancorp's Q3 net loss of $67.5 mln misses analyst expectations
Eagle Bancorp's Q3 net loss of $67.5 mln misses analyst expectations
Oct 22, 2025
Overview * Eagle Bancorp ( EGBN ) Q3 net loss of $67.5 mln, missing analyst expectations * Net interest income rose slightly to $68.2 mln, driven by lower funding costs * Noninterest income fell due to $3.6 mln loan sale loss and $2 mln security sale loss Outlook * Company did not provide specific guidance for future quarters or full...
IT staffing firm ASGN Q3 adjusted EPS beats estimates on growth in consulting business
IT staffing firm ASGN Q3 adjusted EPS beats estimates on growth in consulting business
Oct 22, 2025
Overview * ASGN ( ASGN ) Q3 revenue was $1.01 bln, sligthly beating analyst expectations * Adjusted EPS for Q3 was $1.31, surpassing consensus estimates * Company repurchased 0.9 mln shares for $46 mln, reflecting confidence in financial position Outlook * Company expects Q4 2025 revenue between $960 mln and $980 mln * ASGN ( ASGN ) projects Q4 adjusted...
Kinder Morgan Q3 Adjusted Earnings, Revenue Increase
Kinder Morgan Q3 Adjusted Earnings, Revenue Increase
Oct 22, 2025
04:29 PM EDT, 10/22/2025 (MT Newswires) -- Kinder Morgan ( KMI ) reported Q3 adjusted earnings late Wednesday of $0.29 per share, up from $0.25 a year earlier. Analysts polled by FactSet expected $0.29. Revenue for the quarter ended Sept. 30 was $4.15 billion, up from $3.70 billion a year earlier. Analysts surveyed by FactSet expected $3.98 billion. Kinder Morgan...
Copyright 2023-2026 - www.financetom.com All Rights Reserved